Esperion Therapeutics, Inc. 8-K

What Happened
Esperion Therapeutics, Inc. (ESPR) announced on May 1, 2026 that it entered into a definitive Agreement and Plan of Merger with Essence Parent Inc. and its MergerCo. Under the agreement, MergerCo will merge into Esperion and Esperion will become a wholly owned subsidiary of Parent. The deal provides $3.16 in cash per share plus one contingent value right (CVR) per share; the transaction is expected to close in the third quarter of 2026 and is subject to stockholder approval and customary regulatory clearances.

Key Details

• Per-share consideration: $3.16 in cash plus one CVR per outstanding share (the “Merger Consideration”).
• CVR economics: up to $100 million aggregate in contingent cash payments, split into:
  • Up to $40M if U.S. net sales of bempedoic-acid products (e.g., NEXLETOL®, NEXLIZET®) in 2027 exceed $300M (scales to full $40M at ≥$350M).
  • $60M if U.S. net sales of bumetanide products (e.g., ENBUMYST®) ≥ $160M in any single year through Dec 31, 2030.
• Treatment of equity awards: outstanding RSUs will vest and convert into cash equal to $3.16 plus one CVR; in‑the‑money stock options will vest and convert into cash equal to the excess of $3.16 over the exercise price plus one CVR; certain out-of-the-money or high-strike options are cancelled or subject to special mechanics.
• Approvals, timing and protections: requires Esperion stockholder approval, HSR and a non-U.S. antitrust clearance, no financing condition; expected close Q3 2026; outside date of Nov 1, 2026 (with a limited short extension rule).
• Break fees and financing: Parent must pay a $68,309,078 termination fee in certain circumstances; Esperion would pay $34,154,539 if it terminates to accept a superior proposal; Parent has equity and debt financing commitments and parties included specific-performance remedies for closing.

Why It Matters
For Esperion shareholders, the merger offers immediate, certain cash of $3.16 per share plus potential additional upside through CVRs tied to future U.S. sales of Esperion products—however, CVR payments are conditional on specific sales milestones and are not guaranteed. Employees and option holders should note accelerated vesting and cash‑out mechanics for RSUs and many stock options; some options may be cancelled with no payout. The Board unanimously approved the merger and will recommend stockholder approval, and the company will file a proxy with the SEC with further details for investors to review.